About axsome therapeutics inc - AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
AXSM At a Glance
Axsome Therapeutics, Inc.
One World Trade Center
New York, New York 10007
| Phone | 1-212-332-3241 | | Revenue | 638.50M |
| Industry | Biotechnology | | Net Income | -183,174,000.00 |
| Sector | Health Technology | | 2025 Sales Growth | 65.545% |
| Fiscal Year-end | 12 / 2026 | | Employees | 925 |
|
View SEC Filings
| | | | |
AXSM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.23 |
| Price to Book Ratio | 105.252 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -56.071 |
| Enterprise Value to Sales | 14.066 |
| Total Debt to Enterprise Value | 0.024 |
AXSM Efficiency
| Revenue/Employee | 690,265.946 |
| Income Per Employee | -198,025.946 |
| Receivables Turnover | 2.845 |
| Total Asset Turnover | 1.015 |
AXSM Liquidity
| Current Ratio | 1.555 |
| Quick Ratio | 1.481 |
| Cash Ratio | 0.852 |
AXSM Profitability
| Gross Margin | 91.145 |
| Operating Margin | -26.505 |
| Pretax Margin | -28.771 |
| Net Margin | -28.688 |
| Return on Assets | -29.114 |
| Return on Equity | -252.115 |
| Return on Total Capital | -59.781 |
| Return on Invested Capital | -76.30 |
AXSM Capital Structure
| Total Debt to Total Equity | 247.028 |
| Total Debt to Total Capital | 71.184 |
| Total Debt to Total Assets | 31.62 |
| Long-Term Debt to Equity | 164.374 |
| Long-Term Debt to Total Capital | 47.366 |